pSivida Corp. Reports First Orders for ILUVIEN® Shipped for U.K. National Health Service Hospitals Less Than Seven Weeks After Final NICE Guidance First NHS patient treated on January 10, 2014 Business Wire WATERTOWN, Mass. -- January 13, 2014 pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that its licensee Alimera Sciences has shipped initial orders of ILUVIEN® to several U.K. National Health Service (NHS) facilities and the first NHS patient has received ILUVIEN for the treatment of chronic diabetic macular edema (DME) insufficiently responsive to available therapies. “We are encouraged by the speed with which ILUVIEN has been made available to NHS facilities. These recent ILUVIEN orders reflect the rapid implementation of the final guidance from U.K.’s National Institute for Health and Care Excellence (NICE) recommending ILUVIEN for certain patients with chronic DME,” said Paul Ashton, Ph.D., President and CEO of pSivida. “Many chronic DME patients fail to respond to conventional therapies, continuing to lose vision and facing blindness. ILUVIEN has been shown to stem and even reverse vision loss for many of these patients. pSivida will be entitled to 20% of net profits (as defined) on sales of ILUVIEN for DME by Alimera in the U.K.” On November 27, 2013, NICE published final guidance recommending ILUVIEN as a treatment option for pseudophakic patients (those who have had cataract surgery) with chronic DME insufficiently responsive to available therapies, subject to a patient access scheme. NICE requires clinical commissioning groups, NHS England and local public health authorities to comply with the recommendations in the final guidance within three months of its date of publication. Alimera reported its belief that the speed at which ILUVIEN has been made available at certain NHS facilities is indicative of the unmet need in this chronic DME patient population. Additionally, Alimera reported that on January 10, 2014, the first NHS patient was treated with ILUVIEN, following the first treatments for private pay and insurance patients in the U.K. in 2013. About pSivida Corp. pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drug delivery products designed to deliver drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert™ and BioSilicon™, including Tethadur™. pSivida has instituted the first of two planned pivotal Phase III clinical trials for its lead development product, Medidur™, an injectable, sustained release micro-insert for the treatment of posterior uveitis, a chronic back-of-the-eye disease. ILUVIEN® for the treatment of chronic DME considered insufficiently responsive to available therapies, which uses the same micro-insert as Medidur and is licensed to Alimera Sciences, Inc., is marketed in the U.K. and Germany and has also received marketing authorization in Austria, France, Portugal, and Spain and is awaiting authorization in Italy. Alimera has filed for ten additional EU country approvals through the Mutual Recognition Procedure. pSivida is seeking approval of ILUVIEN in the U.S. An investigator-sponsored clinical trial is ongoing for an injectable, bioerodible micro-insert to treat glaucoma and ocular hypertension, a product candidate on which Pfizer Inc. has an option. pSivida's FDA-approved Retisert®, licensed to Bausch & Lomb Incorporated, provides long-term, sustained drug delivery to treat posterior uveitis. SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. The following are some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements: uncertainties with respect to: Alimera's ability to finance, achieve additional marketing approvals, obtain adequate pricing and reimbursement for, successfully commercialize and achieve market acceptance of, and generate revenues to pSivida from, ILUVIEN for DME in the EU; Alimera's ability to obtain regulatory approval for, and if approved, to finance, successfully commercialize and achieve market acceptance of, and generate revenues to pSivida from, ILUVIEN for DME in the U.S.; the ability to finance, complete and achieve a successful outcome for Phase III trials for, and file and achieve marketing approvals for, Medidur for posterior uveitis, including achieving acceptable risk-to-benefit and safety profiles in light of the CRL for ILUVIEN; initiation, financing and success of Latanoprost Product Phase II trials and any exercise by Pfizer of its option; ability of Tethadur to successfully deliver proteins, peptides and other large biologic molecules; ability to develop product candidates and products and potential related collaborations; initiation and completion of clinical trials and obtaining regulatory approval of product candidates; continued sales of Retisert; adverse side effects; ability to attain profitability; ability to obtain additional capital; further impairment of intangible assets; fluctuations in operating results; decline in royalty income; ability to, and to find partners to, develop and market products; termination of license agreements; competition and other developments affecting sales of products; market acceptance; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; consolidation in the pharmaceutical and biotechnology industries; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; credit and financial market conditions; legislative or regulatory changes; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the SEC. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized. Follow pSivida on social media: Twitter: https://twitter.com/pSividaCorp Facebook: https://www.facebook.com/pages/PSivida-Corp/544893792199562 LinkedIn: http://www.linkedin.com/company/psivida Google+: https://plus.google.com/u/0/b/113754643626984244726/113754643626984244726/posts The President's Blog: http://www.thechairmansblog.com/paul-ashton For more information on pSivida, visit www.psivida.com. Contact: In US: Martin E. Janis & Company, Inc. Beverly Jedynak, +1 312-943-1123 M: +1 773-350-5793 President firstname.lastname@example.org or In Australia: pSivida Corp. Brian Leedman, +61 (0) 41 228 1780 Vice President, Investor Relations email@example.com
pSivida Corp. Reports First Orders for ILUVIEN® Shipped for U.K. National Health Service Hospitals Less Than Seven Weeks After
Press spacebar to pause and continue. Press esc to stop.